4basebio (4BB.L)

Executive Summary

4basebio PLC is a UK-based biotechnology company pioneering a paradigm shift in DNA manufacturing through its proprietary, cell-free TruePrime® enzymatic platform. This technology enables the production of high-purity synthetic DNA (opDNA®) that overcomes the contamination risks, scalability limitations, and bottlenecks of traditional plasmid DNA production. The company's opDNA® is designed for use in next-generation genetic medicines, including mRNA vaccines, gene therapies, and gene editing applications. By eliminating reliance on bacterial fermentation, 4basebio's platform offers faster turnaround times, higher purity, and greater flexibility, positioning it as a key enabler in the rapidly growing synthetic biology and genetic medicine markets. As a publicly traded company on the London Stock Exchange (ticker: 4BB.L), 4basebio is focused on advancing its manufacturing capabilities and forging strategic partnerships. The company is currently in Phase 1/2 development, with a valuation of approximately £74 million. Its proprietary technology has the potential to disrupt the DNA supply chain for pharmaceutical and biotech companies, particularly in the mRNA and gene therapy sectors. Looking ahead, 4basebio aims to achieve GMP certification, secure commercial agreements, and expand its production capacity to meet growing demand. With the increasing adoption of genetic medicines, the company is well-positioned to capitalize on the transition from plasmid-based to synthetic DNA manufacturing, though it remains an early-stage investment with associated risks.

Upcoming Catalysts (preview)

• 2026GMP Certification for opDNA® Manufacturing Facility60% success
• Q4 2026First Commercial Supply Agreement with a Pharma Partner40% success
• Q3 2026Publication of Preclinical Data Demonstrating Superiority of opDNA® Over Plasmid DNA70% success